Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that EGFR p.L858R status confers therapeutic sensitivity to Erlotinib, Ramucirumab in patients with Non-Small Cell Lung Cancer.
The U.S. Food and Drug Administration granted approval to ramucirumab in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
This statement is based on a regulatory approval from the Food and Drug Administration:
CYRAMZA is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.